BLife’s Team

BLife’s Team
Ahmad Doroudian, PhD

Ahmad Doroudian, PhD Chief Executive Officer & Director

  • 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
  • Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
  • Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD

Hooshmand Sheshbaradaran, PhD Chief Operating Officer

  • 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
  • Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
  • Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Angela Ogden, MD

Angela Ogden, MD Chief Medical Officer

  • 25+ year senior executive-level experience developing therapeutics from preclinical to launch including several blockbusters; plus 10+ years senior level academic medicine experience.
  • Senior executive roles at Pharmacia/Pfizer, BMS, JNJ, BTG
  • Development of Abraxane®, Aromasin®, Celebrex®, Dacogen®, Erbitux®, Folotyn®, TheraSphere®, Varithena®, Velcade®
Moira Ong, CPA, CA

Moira Ong, CPA, CA Chief Financial Officer

  • 18+ years experience as VP of Finance & CFO in several private and public companies including Merus Labs (NASDAQ: MSLI), BetterLife Pharma (CNSX: BETR; formerly Pivot Pharmaceuticals)
  • Managed the integration of the supply chain management and accounting Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc.
  • Previously at Grant Thornton and Deloitte
Jeff Fellows

Jeff Fellows Head of Regulatory

  • 30+ years of drug development experience leading regulatory development efforts
  • Worked with early stage development companies and a large multinational biopharmaceutical enterprise developing programs across numerous therapeutic areas
  • Previously VP of Regulatory Affairs at Cell Therapeutics (currently CTI BioPharma, NASDAQ and MTA: CTIC), held senior positions in Regulatory Affairs at Amgen
Joseph Lamendola, PdD

Joseph Lamendola, PdD Regulatory Strategy Advisor

  • 30+ years senior executive-level experience in pharma global regulatory from pre-IND to NDA
  • Senior executive roles at Schering Plough / Merck; Bristol-Myers Squibb
  • Filed and approved near 30 NDAs in ten different therapeutic areas
Scott Rudge, PdD

Scott Rudge, PdD CMC Head

  • 30+ years senior executive-level experience in pharma global regulatory from pre-IND to NDA
  • Senior executive roles at Schering Plough / Merck; Bristol-Myers Squibb
  • Filed and approved near 30 NDAs in ten different therapeutic areas
Dawn East

Dawn East Head Clinical Operations

  • 30+ years senior executive-level experience in pharma global regulatory from pre-IND to NDA
  • Senior executive roles at Schering Plough / Merck; Bristol-Myers Squibb
  • Filed and approved near 30 NDAs in ten different therapeutic areas
Raj Dua, PhD

Raj Dua, PhD Head AP-002 CMC

  • 30+ years senior executive-level experience in pharma global regulatory from pre-IND to NDA
  • Senior executive roles at Schering Plough / Merck; Bristol-Myers Squibb
  • Filed and approved near 30 NDAs in ten different therapeutic areas
Gary Camblin

Gary Camblin Head Bioanalytics

  • 30+ years senior executive-level experience in pharma global regulatory from pre-IND to NDA
  • Senior executive roles at Schering Plough / Merck; Bristol-Myers Squibb
  • Filed and approved near 30 NDAs in ten different therapeutic areas
Bianna Gal

Bianna Gal QA-QC

  • 20+ years of experience in quality assurance, compliance and validation
  • Previously Director of Quality Assurance at IRX Therapeutics and Pharmaceutical Product Assurance Senior Release Specialist at Pfizer

Our Advisory Board

Mark is editor-in-chief and founder of BioPub, a small-cap biotech investing situations analysis website with a global following. He graduated summa cum laude from University of North Carolina with a chemistry and was a rare junior-year inductee into Phi Beta Kappa. In the NIH-sponsored Medical Scientist Training Program at Duke University, he earned an MD with junior election to Alpha Omega Alpha and a PhD in biochemistry and cell biology with special distinction. He trained in categorical internal medicine at Duke, completed post-doctoral work in distintegrins at National Taiwan University (Taipei), and returned to Duke for research and clinical fellowships in gastroenterology and transplant hepatology. After serving on the faculties of Duke, where he was awarded the medical center’s highes teaching honor, and later University of Texas MD Anderson Cancer Center (Houston), where he was elected to the faculty senate, and UT Health Science Center in Houston,  he established an independent freestanding hepatology clinic and clinical research institute, leading clinical trials for a large number of pharma companies and speaking nationally on interferon therapeutics for virus hepatitis as a key opinion leader for many years. He authored more than three dozen peer-reviewed publications and chapters, over 100 abstracts, and was elected Fellow of the American College of Physicians in 2002. With an impressive record of success in biotech investing and analysis, and the growing success of BioPub, he decided to devote all energies to guiding biotech investors, analyzing investing situations, and serving as a consultant to the biotech industry.
Tony is one of the most experienced Investment Bankers in Canada in the healthcare and biotechnology industry sectors. In 1987, Tony was instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital. Most recently, Tony was an investment banker in the healthcare and biotechnology industries with Dominick Capital Corp.